康莱特注射液对乙肝相关性肝癌患者恩替卡韦抗病毒活性作用的影响

Effect of Kanglaite Injection on Antiviral Activity of Entecavir in Patients with Hepatitis B-related Liver Cancer

目的:探讨康莱特注射液对乙肝相关性肝癌患者恩替卡韦抗病毒活性作用的影响。方法:回顾性分析2020年1月—2022年3月新余钢铁集团有限公司中心医院119例乙肝相关性肝癌患者,根据治疗方法分为两组,分别为联合用药组(n=62)和恩替卡韦组(n=57)。恩替卡韦组给予0.5 mg恩替卡韦胶囊口服治疗,联合用药组在恩替卡韦组的基础上加用康莱特注射液(静脉滴注100 mL)。均治疗6个月。比较两组疗效、凝血功能指标、肝功能指标及不良反应。结果:联合用药组总有效率(87.10%)高于恩替卡韦组(71.93%),差异有统计学意义(P<0.05)。治疗前,两组凝血功能指标比较,差异均无统计学意义(P>0.05);治疗后,两组凝血功能指标均有所改善,且联合用药组的活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)及血浆纤维蛋白原(FIB)均低于恩替卡韦组,差异均有统计学意义(P<0.05)。治疗前,两组肝功能指标比较,差异均无统计学意义(P>0.05);治疗后,两组肝功能指标均有所改善,且治疗后联合用药组的谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素水平(TBIL)、乙肝病毒基因(HBV-DNA)及甲胎蛋白(AFP)均低于恩替卡韦组,而联合用药组的白蛋白(ALB)则高于恩替卡韦组,差异均有统计学意义(P<0.05)。联合用药组的不良反应总发生率(27.42%)高于恩替卡韦组(19.30%),但差异无统计学意义(P>0.05)。结论:康莱特注射液联合恩替卡韦能够有效治疗乙肝相关性肝癌患者,有效抑制HBV-DNA,且其血液功能和肝功能指标均能得到有效改善。

Objective:To investigate the effect of Kanglaite Injection on the antiviral activity of Entecavir in patients with hepatitis B-related liver cancer.Method:A retrospective analysis of 119 patients with hepatitis B-related liver cancer in Central Hospital of Xinyu Iron and Steel Group Co.,LTD.from January 2020 to March 2022 was conducted.According to the treatment methods,they were divided into the combined treatment group(n=62)and the Entecavir group(n=57).The Entecavir group was treated with 0.5 mg Entecavir Capsules orally,and the combined treatment group was treated with Kanglaite Injection(intravenous drip 100 mL)on the basis of the Entecavir group.All patients were treated for 6 months.The efficacy,coagulation function indexes,liver function indexes and adverse reactions were compared between the two groups.Result:The total effective rate of the combined treatment group(87.10%)was higher than that(71.93%)of the Entecavir group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in coagulation function between the two groups(P>0.05).After treatment,the coagulation function indexes of both groups were improved,and the activated partial thrombin time(APTT),thrombin time(TT),prothrombin time(PT)and plasma fibrinogen(FIB)of the combined treatment group were lower than those of the Entecavir group,with statistical significance(P<0.05).Before treatment,there were no significant differences in liver function indexes between the two groups(P>0.05).After treatment,liver function indexes of both groups were improved,and the levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),hepatitis B virus gene(HBVDNA)and alpha-fetoprotein(AFP)in the combined treatment group were lower than those in the Entecavir group,the albumin(ALB)in the combined treatment group was higher than that in the Entecavir group,the differences were statistically significant(P<0.05).The total incidence of adverse reactions in the combined treatment group(27.42%)was higher than that(19.30%)in the Entecavir group,but the difference was not statistically significant(P>0.05).Conclusion:Kanglaite Injection combined with Entecavir can effectively treat patients with hepatitis B-related liver cancer,effectively inhibit HBV-DNA,and improve their blood function and liver function.